ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 1063 • ACR Convergence 2020

    Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro

    Christina Bax1, Yubin Li1, Spandana Maddukuri2, Adarsh Ravishankar3, Jay Patel3, Daisy Yan1, Josef Symon Concha1 and Victoria Werth1, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 3University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia

    Background/Purpose: Spirulina, a popular herbal supplement, stimulates the immune system, as determined by in vitro and in vivo studies. Our recent epidemiologic data suggest that Spirulina…
  • Abstract Number: 1916 • ACR Convergence 2020

    KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model

    Marta Del Rio Oliva1, Michael Basler1, Darrin Bomba2, Diana Lam2, Jennifer Brandl2, Christopher Kirk2 and Marcus Groettrup1, 1University of Konstanz, Konstanz, Germany, 2Kezar Life Sciences, Inc, San Francisco, CA

    Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are…
  • Abstract Number: 1065 • ACR Convergence 2020

    Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis

    Adarsh Ravishankar1, Daisy Yan2, Christina Bax3, Josef Symon Concha2, Bridget Shields4, Lisa Pappas-Taffer4, Rui Feng5, Joyce Okawa4 and Victoria Werth2, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 5University of Pennsylvania, Philadelphia

    Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…
  • Abstract Number: 1949 • ACR Convergence 2020

    CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro

    Spandana Maddukuri1, Jay Patel2, Christina Bax3, Maria Wysocka3 and Victoria Werth4, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia

    Background/Purpose: Dermatomyositis (DM) patients report poor quality of life due to disease activity and persistent itch. Lenabasum is an oral non-immunosuppressive, non-psychoactive cannabinoid type 2…
  • Abstract Number: 1067 • ACR Convergence 2020

    Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease

    Takahisa Gono1, Yuka Okazaki1 and Masataka Kuwana2, 1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan

    Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with interstitial lung disease (ILD), which often represents rapidly progressive course and fatal outcomes. Circulating levels…
  • Abstract Number: 1988 • ACR Convergence 2020

    Skin Disease More Recalcitrant to Intervention Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis

    Andi Wang1, Gabrielle Morgan2, Chiang-Ching Huang3, Amy Paller4 and Lauren Pachman5, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Joseph J. Zilber School of Public Health, Milwaukee, 4Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, 5Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL

    Background/Purpose: Persistent skin manifestations, in particular calcinosis, contribute to significant morbidity in patients with JDM. The goal of this study was to compare the course…
  • Abstract Number: 1068 • ACR Convergence 2020

    Efficacy of Early Initiation of Plasma Exchange Therapy for a Patient with Anti-MDA5 Autoantibody-Positive Dermatomyositis Developing Refractory Rapidly Progressive Interstitial Lung Disease

    Noriko Sasaki1, Akira Ishii1, Keigo Shimura1, Azusa Kojima1, Mai Sugiyama2, Yuto Izumi1, Kazuki Hirano1, Sho Sasaki2, Takayoshi Kurabayashi1, Yuji Hosono2, Chiho Yamada2 and Shinji Sato2, 1Tokai University School of Medicine, Isehara, Kanagawa, Japan, 2Tokai University School of Medicine, Isehara, Japan

    Background/Purpose: Dermatomyositis (DM), and particularly the subtype clinically amyopathic DM (CADM), is often associated with fatal rapidly progressive interstitial lung disease (RP-ILD) when anti-melanoma differentiation-associated…
  • Abstract Number: 1990 • ACR Convergence 2020

    Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

    Hanna Kim1, Lylan Bergeron2, Samantha Dill2, Michelle O'Brien2, Laura Vian3, Minal Jain4, Manuk Manukyan2, Xiaobai Li5, Shajia Lu3, Wanxia L. Tsai3, Kalyani Mishra Thakur6, Yinghui Shi6, Massimo Gadina7, April Brundidge2, Michelle Millwood2, Lisa G. Rider8 and Robert Colbert2, 1Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, 2Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 3Translational Immunology Section, NIAMS, NIH, Bethesda, MD, 4Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, 5Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, 6Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 7National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 8Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD

    Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
  • Abstract Number: 1071 • ACR Convergence 2020

    Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore

    Choon Guan Chua1, Jia Zhen Low1 and Mona Manghani1, 1Tan Tock Seng Hospital, Singapore, Singapore

    Background/Purpose: Anti-transcription intermediary factor 1-gamma autoantibody (anti-TIF-1ƴ Ab) associated dermatomyositis (DM) is strongly associated with the occurrence of malignancies. Patients may develop cancers prior to, concurrent…
  • Abstract Number: 1080 • ACR Convergence 2020

    Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America

    Antonia Maria Valenzuela Vergara1, Magdalena Torres1 and Alejandro Deves1, 1Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterized by muscle inflammation and internal organ involvement. The Bohan & Peter (B&P) criteria…
  • Abstract Number: 1085 • ACR Convergence 2020

    Pain in Myositis Is Associated with the Disease Activity

    Anjana Chandrasekhara Pillai1, Chester Oddis2, Siamak Moghadam-Kia3, Dana Ascherman4, Nicole Neiman5, Diane Koontz5, Ren Dianxu5 and Rohit Aggarwal4, 1UPMC Mckeesport, Pittsburgh, PA, 2Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA, 5UPMC, Pittsburgh, PA

    Background/Purpose: Pain in myositis is poorly studied and multifactorial relating to muscle weakness, arthritis, myofasciitis, fibromyalgia or other co-morbidities. We sought to prospectively evaluate patient-reported…
  • Abstract Number: 1087 • ACR Convergence 2020

    Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis

    Yubin Li1, Christina Bax2, Jay Patel3, Adarsh Ravishankar3, Krisha Desai4, Majid Zeidi4, Muhammad Bashir4 and Victoria Werth1, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2University of Pennsylvania, Department of Dermatology, Philadelphia, 3University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 4University of Pennsylvania, Philadelphia

    Background/Purpose: Dermatomyositis (DM) is an acquired inflammatory myopathy characterized by chronic skin inflammation. The pathogenesis of DM is still unclear. Extracellular vesicles (EVs) are lipid…
  • Abstract Number: 0085 • ACR Convergence 2020

    Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition

    Fadi Charouf1, Netanel Karbian1, Itamar Altman1, Yakov Fellig1 and Dror Mevorach1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
  • Abstract Number: 1094 • ACR Convergence 2020

    Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis

    Julie Paik1, Jemima Albayda1, Eleni Tiniakou1, Grazyna Purwin1, Andrew Koenig2 and Lisa Christopher-Stine1, 1Johns Hopkins University, Baltimore, MD, 2Pfizer Inc, New York City, NY

    Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…
  • Abstract Number: 0531 • ACR Convergence 2020

    The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records

    Sunali Goonesekera1, Ankit Bansal1, Swarali Tadwalkar2 and Alison Isherwood3, 1Decision Resources Group, Part of Clarivate, Boston, MA, 2Decision Resources Group, part of Clarivate, Bangolore, India, 3Decision Resources Group, part of Clarivate, London, United Kingdom

    Background/Purpose: Epidemiological studies suggest differences in the prevalence and disease severity of certain autoimmune diseases by race and ethnicity. In this study, we evaluate the…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology